Company Overview
Snapshot
Founded in May 2020 by Gabby Sarusi, Flanimus operates with 1–10 employees. The company's innovative breathalyzer test for coronavirus diagnosis was developed during its participation in the Oazis accelerator program, which ran from May to September 2020.
Business overview
Flanimus is a Health Tech & Life Sciences company focused on developing a rapid, cost-effective diagnostic solution for coronavirus. The company's core product is a breathalyzer test designed for ease of use, enabling diagnosis at any location without specialized staff or laboratory equipment. This technology utilizes a disposable capsule with an embedded chip and a spectrometer to detect the virus's spectral signature through proprietary software. Flanimus operates within the Medical Devices and Digital Healthcare sectors, specifically targeting digital medical diagnostics and diagnostics devices, with potential applications in markets such as travel and tourism.
Log in to access full profile ›Company Intelligence Q&A
- What is Flanimus's primary product?
- Flanimus develops a simple, one-minute breathalyzer test for diagnosing the coronavirus. The test is designed to be cost-effective at three dollars per test.
- How does the Flanimus diagnostic device work?
- The device consists of a disposable capsule with a chip and a spectrometer. After a user breathes into the capsule, it is inserted into the spectrometer, which then detects the spectral signature of the virus using proprietary software.
- What are the key advantages of the Flanimus test?
- The Flanimus test can be performed at any location and by any operator, eliminating the need for trained staff or dedicated laboratories, making it highly accessible and efficient.
- When was Flanimus founded?
- Flanimus was founded in May 2020.
- Who is a founder of Flanimus?
- Gabby Sarusi is a founder of Flanimus.